Media
Press Release
23
2024.01
Recbio Enters a License and Strategic Cooperation with SPIMACO for Recombinant HPV-9 Vaccine in 15 countries in the Middle East and North Africa.
29
2023.12
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio’s Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
23
2023.10
Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair
09
2023.10
Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre
Publications
2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Download
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques